Immunotherapy of Malignant Melanoma with Tumor Lysate-Pulsed Autologous Monocyte-Derived Dendritic Cells
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. Materials and Methods: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4×10^7 DC were injected each time. Results: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. Conclusion: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.
Abstract
Purpose: Dendritic cell (DC) vaccination for melanoma was introduced because melanoma carries distinct tumor-associated antigens. The purpose of this study was to investigate the efficacy and safety of DC vaccination for melanoma in Korea. Materials and Methods: Five patients with stage IV and one with stage II were enrolled. Autologous monocyte-derived DCs (MoDCs) were cultured and pulsed with tumor-lysate, keyhole limpet hemocyanin, and cytokine cocktail for mature antigen-loaded DC. DC vaccination was repeated four times at 2-week intervals and 2-4×10^7 DC were injected each time. Results: Reduced tumor volume was observed by PET-CT in three patients after DC vaccination. Delayed type hypersensitivity responses against tumor antigen were induced in five patients. Tumor antigen-specific IFN-γ-producing peripheral blood mononuclear cells were detected with enzyme-linked immunosorbent spot in two patients. However, the overall clinical outcome showed disease progression in all patients. Conclusion: In this study, DC vaccination using tumor antigen-loaded, mature MoDCs led to tumor regression in individual melanoma patients. Further standardization of DC vaccination protocol is required to determine which parameters lead to better anti-tumor responses and clinical outcomes.
참고문헌 (21)
- Hall HI, "Update on the incidence and mortality from melanoma in the United States", J Am Acad Dermatol, 40, pp.35~42 (1999)
- Houghton AN, "Immunity against cancer: lessons learned from melanoma", Curr Opin Immunol, 13, pp.134~140 (2001)
- de Braud F, "Cascinelli N. Malignant melanoma", Crit Rev Oncol Hematol, 47, pp.35~63 (2003)
- Hsu FJ, "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells", Nat Med, 2, pp.52~58 (1996)
- Schuler G, "The use of dendritic cells in cancer immunotherapy", Curr Opin Immunol, 15, pp.138~147 (2003)
- Kim S, "Monocyte enrichment from leukapheresis products by using the Elutra cell separator", TRANSFUSION, 47, pp.2290~2296 (2007), BLACKWELL PUBLISHING
- Eubel J, "Dendritic cell vaccination as a treatment modality for melanoma", Expert Rev Anticancer Ther, 9, pp.1631~1642 (2009)
- Nakai N, "Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells", J Dermatol, 33, pp.462~472 (2006)
- López MN, "Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells", J Clin Oncol, 27, pp.945~952 (2009)
- Jonuleit H, "Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood", J Exp Med, 193, pp.1285~1294 (2001)
- Liyanage UK, "Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma", J Immunol, 169, pp.2756~2761 (2002)
- Curiel TJ, "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival", Nat Med, 10, pp.942~949 (2004)
- Mahnke K, "Immature, but not inactive: the tolerogenic function of immature dendritic cells", Immunol Cell Biol, 80, pp.477~483 (2002)
- Dannull J, "Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells", J Clin Invest, 115, pp.3623~3633 (2005)
- Mahnke K, "Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro", Int J Cancer, 120, pp.2723~2733 (2007)
- Rasku MA, "Transient T cell depletion causes regression of melanoma metastases", J Transl Med, 6, pp.12~ (2008)
- Attia P, "Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma", J Immunother, 28, pp.582~592 (2005)
- Lee TH, "Development of an Effective Method for Dendritic Cell Immunotherapy of Mouse Melanoma", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 70, pp.85~92 (2009), BLACKWELL PUBLISHING
- Jonuleit H, "A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection", Int J Cancer, 93, pp.243~251 (2001)
- Tuettenberg A, "Induction of strong and persistent MelanA", MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients, 2006, pp.118, 2617~2627
- Whiteside TL, "The tumor microenvironment and its role in promoting tumor growth", Oncogene, 27, pp.5904~5912 (2008)